Incepta Pharmaceuticals | Product details

Home > Products > Ocarnix

Ocarnix (Levocarnitine)

Therapeutic Group: Vitamins and Minerals

Presentation
Descriptions
Indications
Dosage & Administration
Side Effects
Precautions
Use in Pregnancy & Lactation
Overdose
Commercial Packaging

Presentation

Ocarnix tablet: Each tablet contains Levocarnitine USP 330 mg.

Descriptions

Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production

Indications

Chronic Fatigue Syndrome

Heart Diseases

Congestive Heart Failure

Kidney Disease

High Cholesterol

Intermittent Claudication

Dementia and memory impairment

Down Syndrome

Male infertility

Hyperthyroidism

Dosage & Administration

Ocarnix tablet
Adults: 330 mg two or three times daily. Depending on clinical response.
Infants and children: 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.

Side Effects

Generally Levocarnitine is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur

Precautions

Gastrointestinal reactions may result from a too rapid consumption of Levocarnitine.
The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine

Use in Pregnancy & Lactation

There is no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.
Levocarnitine supplementation in nursing mothers has not been specifically studied. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment

Overdose

There have been no reports of toxicity from levocarnitine overdosage

Commercial Packaging

Ocarnix tablet: Each box contains 5 Alu-Alu blister strips of 4 tablets.

Vitamins and Minerals